Boston Common Asset Management LLC Takes Position in argenex SE $ARGX

Key Points

• Boston Common Asset Management initiated a new stake in argenex SE in the first quarter, buying 3,753 shares valued at about $2.74 million.
• Several other institutional investors also adjusted their positions, and institutions now own about 60.32% of the company’s stock.
• Analysts remain broadly positive on ARGX, with an average rating of “Moderate Buy” and a consensus price target of $1,037.61; the stock recently traded at $860.55.

Boston Common Asset Management LLC bought a new position in argenex SE (NASDAQ:ARGX - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 3,753 shares of the company's stock, valued at approximately $2,741,000.

Other large investors have also recently modified their holdings of the company. Assenagon Asset Management S.A. purchased a new position in shares of argenex during the 4th quarter worth about $20,475,000. Sivik Global Healthcare LLC bought a new position in argenex during the 4th quarter valued at about $1,261,000. Mirae Asset Global Investments Co. Ltd. raised its position in argenex by 22.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,846 shares of the company's stock worth $9,121,000 after purchasing an additional 2,018 shares during the period. SG Americas Securities LLC raised its position in argenex by 94.9% in the 4th quarter. SG Americas Securities LLC now owns 3,179 shares of the company's stock worth $2,673,000 after purchasing an additional 1,548 shares during the period. Finally, M&T Bank Corp lifted its stake in argenex by 34.8% in the fourth quarter. M&T Bank Corp now owns 4,980 shares of the company's stock worth $4,188,000 after purchasing an additional 1,286 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

Analyst Ratings Changes

ARGX has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $940.00 target price on shares of argenex in a research report on Thursday, June 25th. Glj Research upgraded argenex to a "strong-buy" rating in a report on Friday, April 3rd. Wells Fargo & Company raised their price target on argenex from $1,260.00 to $1,291.00 and gave the stock an "overweight" rating in a research note on Monday, June 1st. Weiss Ratings raised argenex from a "hold (c)" rating to a "hold (c+)" rating in a research note on Monday, July 6th. Finally, Bank of America boosted their price objective on argenex from $1,016.00 to $1,088.00 and gave the company a "buy" rating in a report on Thursday, July 2nd. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,037.61.

argenex Price Performance

Shares of ARGX opened at $860.55 on Monday. The firm has a market capitalization of $53.84 billion, a price-to-earnings ratio of 38.31, a PEG ratio of 1.06 and a beta of 0.45. argenex SE has a 1-year low of $560.91 and a 1-year high of $953.58. The company has a 50-day moving average of $860.97 and a 200 day moving average of $813.43.

argenex (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The business had revenue of $1.31 billion for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. On average, equities analysts anticipate that argenex SE will post 26.27 earnings per share for the current fiscal year.

argenex Profile

argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.